Autoimmune diseaseImmunology & inflammationHematologyRare disease PKPD

Sutimlimab exposure and hemoglobin response

Reference paper ↗

A two-compartment PK/PD model coupling sutimlimab linear and nonlinear disposition to concentration-dependent recovery and turnover of hemoglobin.

Therapeutic
Sutimlimab
Modality
Monoclonal antibody
Target
Complement C1s
Disease
Cold agglutinin disease
Model type
PKPD

Complete model workspace

Checking workspace access…

Parameters
27
States
5
Equations
5
Derived outputs
9

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Approved 6.5 g regimen, 65 kg

How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response? Explore this intervention regimen through Central sutimlimab concentration, Hemoglobin, Sutimlimab pharmacodynamic effect, Cumulative sutimlimab exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–2.50e+4 hour; step 24

InputDefaultAvailable range
Systemic clearance5.69 mL/hour2.845–8.535 mL/hour
Central distribution volume3.83 L1.915–5.745 L
Maximum elimination rate9.85 mg/hour4.925–14.77 mg/hour
Half-maximal effect concentration155 ug/mL77.5–232.5 ug/mL
Turnover time188 hour94–282 hour

Expected readouts

Central sutimlimab concentration · Hemoglobin concentration (g/dL) · Sutimlimab pharmacodynamic effect · Exposure (AUC) (h*ug/mL)

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 27 declared model parameters.

More key parameters (1)

How the model represents the biology

A two-compartment PK/PD model coupling sutimlimab linear and nonlinear disposition to concentration-dependent recovery and turnover of hemoglobin.

How does sutimlimab exposure alter empirical hemoglobin turnover?Intravenous sutimlimab enters a central pool, exchanges with a peripheral pool, and undergoes linear plus saturable clearance. Central concentration generates an empirical Emax effect that reduces modeled hemoglobin loss, while hemoglobin production remains fixed and drug exposure accumulates.BIOLOGY OVERVIEWHow does sutimlimab exposure alter empirical hemoglobin turnover?IV sutimlimabInfusion to central amountCentral exposureSutimlimab concentrationPeripheral poolReversible distributionPK clearanceLinear and saturable lossEmpirical drug effectConcentration-dependent EmaxHemoglobin turnoverDrug effect reduces modeledlossCumulative exposureCentral concentration integralPRIMARY READOUTSCentral sutimlimab concentrationCentral sutimlimab concent…HemoglobinHemoglobinDrug-effect fractionDrug-effect fractionCumulative exposureCumulative exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: An explicit C1s or classical-complement state, complement cascade, hemolysis or red-cell pools, and transfusion events are not represented; concentration acts empirically on hemoglobin loss.

Modeled relationships (6)
  • IV sutimlimab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → PK clearance: linear + saturable (loss)
  • Central exposure → Empirical drug effect: Emax effect (modulation)
  • Empirical drug effect → Hemoglobin turnover: reduces Hb loss (modulation)
  • Central exposure → Cumulative exposure: integrates C (production)

Modeled relationships: IV sutimlimab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to PK clearance: linear + saturable (loss); Central exposure to Empirical drug effect: Emax effect (modulation); Empirical drug effect to Hemoglobin turnover: reduces Hb loss (modulation); Central exposure to Cumulative exposure: integrates C (production).

Primary readouts: Central sutimlimab concentration; Hemoglobin; Drug-effect fraction; Cumulative exposure.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID frank_2023_sutimlimab_cad_pkpd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics